ABBVIE WKN: A1J84E ISIN: US00287Y1091 Forum: Aktien Thema: Hauptdiskussion

The pessimism surrounding AbbVie has pushed its dividend yield to around 5%. The combination of a high yield, low valuation and solid growth prospects makes AbbVie a strong choice for any investor looking for current income, income growth and exposure to the pharmaceutical industry.

The company has invested heavily in its new product pipeline, spending between $4 billion and $5 billion a year on research and development in fiscal 2015 through fiscal 2017. The company is also engaging heavily in share repurchases. In addition to share repurchases, AbbVie also returns around 45% of earnings to shareholders via dividend payments.

AbbVie, one of the world’s largest biopharmaceutical companies, was created in 2013 when it was spun-off from Abbott Laboratories. The company has grown its adjusted earnings-per-share each year since it was spun off. From fiscal 2013 through fiscal 2017 adjusted earnings-per-share have compounded at a strong 15.6% rate. While AbbVie’s business results have been excellent, the market has not fully appreciated the stock. AbbVie generates nearly 60% of its revenue from the drug Humira. The drug has already begun to fall off the patent cliff, but results have been much better than previously thought. In fact, Humira sales are still growing as AbbVie both vigorously defends its patent position and continues to find new use cases for Humira.

Earnings over the next five years are expected to be even better than the last five. With a yield of 5%, the stock has a spectacular track record and offers more growth and a higher dividend than any other big drug company.

The rapid growth has been achieved from its blockbuster biologic autoimmune drug Humira, which is the world’s number one drug, with annual sales of over $20 billion. Humira accounts for over 50% of sales and faces increasing competition that will erode market share. However, AbbVie has a spectacular pipeline of new drugs that should more than offset the slippage. According to market research firm EvaluatePharma, AbbVie has the second most valuable clinical pipeline across all of biopharma. It has 20 new products slated for launch by 2020 and 15 drugs and treatments that are already currently already in phase 3, the last step before the approval process.

AbbVie is a U.S.-based biopharmaceutical company specializing in cutting edge small molecule drugs. The company has already eclipsed its former parent company in size and is now the eighth largest drug company in the world. Since the stock’s IPO on December 21, 2012 it has provided a phenomenal average annual return of 20%. An initial $10,000 investment would now be worth over $31,000, with dividends reinvested. The dividend has more than doubled since 2014 and the stock now yields a big fat 5%.

https://www.google.de/amp/s/www.forbes.com/sites/moneyshow/2019/01/17/four-top-stock-picks-for-2019-abbvie-ibm-mccormick-and-starbucks/amp/

Study links opioid prescriptions to marketing spendhttps://seekingalpha.com/news/3424334

Bin mal mit dabei, 1.Position ✌️

Die Aktie ist 1,72% im premarket (vor Eröffnung) gestiegen

Danke für die Info! Was bedeutet denn "Shares +1.72% PM"?

Sieht doch gut aus, Gewinn wieder kräftig gesteigert. AbbVie (NYSE:ABBV): Q3 Non-GAAP EPS of $2.14 beats by $0.13; GAAP EPS of $1.81 beats by $0.06. Revenue of $8.24B (+17.7% Y/Y) beats by $20M. Shares +1.72% PM. Quelle: Seeking Alpha

So das war heute morgen also eine gute Gelegenheit zuzusteigen...

Die Eigenkapitalrendite klingt ja unglaublich aber Verschuldunggrad und EK sind extrem.

Hmmm habe auch keine News gefunden. Ist jedenfalls sehr attraktiv bewertet.

Div rendite ist jetzt >4,5%